PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Cost reduction while TRVN shows 98.86% growth. Joel Greenblatt would examine competitive advantage.
4.31%
Positive growth while TRVN shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth 50-75% of TRVN's 6.74%. Bruce Berkowitz would examine spending effectiveness.
-40.17%
G&A reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-8.25%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Both companies reducing D&A. Martin Whitman would check industry patterns.
8.31%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Similar other expenses growth to TRVN's 159.17%. Walter Schloss would investigate industry patterns.
12.55%
Pre-tax income growth exceeding 1.5x TRVN's 1.02%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
12.55%
Net income growth exceeding 1.5x TRVN's 1.02%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
15.52%
Similar EPS growth to TRVN's 17.92%. Walter Schloss would investigate industry trends.
15.52%
Similar diluted EPS growth to TRVN's 17.92%. Walter Schloss would investigate industry trends.
3.21%
Share count reduction exceeding 1.5x TRVN's 20.59%. David Dodd would verify capital allocation.
3.21%
Diluted share reduction exceeding 1.5x TRVN's 20.59%. David Dodd would verify capital allocation.